Results 141 to 150 of about 5,752,243 (395)

Risk of Multiple Myeloma In Rheumatoid Arthritis: A Meta-Analysis of Case-Control and Cohort Studies

, 2014
Multiple myeloma is a malignant neoplasm of plasma cells mainly affecting elderly patients. Despite the wealth of information available on therapeutic strategies, the etiology and pathogenesis of myeloma remain unclear.
Li, Jian, Shen, Kaini, Wu, Qing, Xu, Gufeng, Zhou, Daobin   +4 more
core   +3 more sources

Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma [PDF]

, 2012
BACKGROUND: Multiple myeloma is a plasma cell disorder that is characterised by clonal proliferation of malignant plasma cells in the bone marrow, monoclonal paraprotein in the blood or urine and associated organ dysfunction.
A Chikh, A Git, A J King, AM Roccaro, BA Walker, C I Jones, C Roth, CI Jones, CS Neal, E Borek, F Pichiorri, G A Horne, G Reid, H J S Stewart, HM Heneghan, I Faraoni, J Speer, K Zen, M Lionetti, M V Zabolotskaya, MJ Lodes, MP Hunter, PS Mitchell, RA Kyle, RA Kyle, S F Newbury, SH Swerdlow, T J Chevassut, W Zhu, X Chen, YW Kong   +30 more
core   +1 more source

International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight ...
Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, Asami Nishikori, Remi Sumiyoshi, Hideki Ujiie, Yuri Kawahara, Tomohiro Koga, Masao Ueki, Dorottya Laczko, Eric Oksenhendler, David C. Fajgenbaum, Frits van Rhee, Atsushi Kawakami, Yasuharu Sato   +14 more
wiley   +1 more source

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2016
BACKGROUND Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory ...
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis, M. Hansson, L. Pour, I. Sandhu, P. Ganly, B. Baker, S. Jackson, A. Stoppa, D. Simpson, P. Gimsing, A. Palumbo, L. Garderet, M. Cavo, Shaji K. Kumar, C. Touzeau, F. Buadi, J. Laubach, D. Berg, Jianchang Lin, A. Di Bacco, A. Hui, H. V. D. van de Velde, P. Richardson   +25 more
semanticscholar   +1 more source

Hyperlipidemic myeloma: review of 53 cases [PDF]

, 2018
Hyperlipidemic myeloma is a rare and poorly understood variant of multiple myeloma. We report the case of a 53-year-old woman with hyperlipidemic myeloma, skin xanthomas and hyperviscosity syndrome who underwent allogeneic bone marrow transplantation.
Goede, Jeroen, Misselwitz, Benjamin, Pestalozzi, Bernhard, Schanz, Urs, Seebach, Jörg   +4 more
core  

Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]

, 2017
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana, Cippitelli, Marco, Fionda, Cinzia, Santoni, Angela, Soriani, Alessandra, Zingoni, Alessandra   +5 more
core   +1 more source

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution

American Journal of Hematology, EarlyView.
9% of patients with multiple myeloma achieve 15‐year progression‐free survival; Kaplan‐Meier curves for PFS (A) and OS (B). ABSTRACT The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their
Meletios A. Dimopoulos, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Foteini Theodorakakou, Eirini Solia, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Erasmia Psimenou, Stavroula Giannouli, Nikolaos Kanellias, Vassilis Koutoulidis, Maria Roussou, Angeliki Andrikopoulou, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis   +17 more
wiley   +1 more source

Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth

Haematologica
Multiple myeloma (MM) is a plasma cell malignancy considered incurable despite the recent therapeutic advances. Effective targeted therapies are therefore needed.
Yao Yao, Shuhui Deng, Jessica Fong Ng, Mei Yuan, Chandraditya Chakraborty, Vera JoyWeiler, Nikhil Munshi, Mariateresa Fulciniti   +7 more
doaj   +1 more source

Investigation of urinary proteins in multiple myeloma by means of salting-out analysis [PDF]

, 1955
Elizabeth P. Steyn-Parvé, O. J. Ten Thije   +1 more
openalex   +1 more source

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma [PDF]

, 2019
Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no identified characteristics in the diagnosis of MGUS that have been helpful in ...
Allegra A., Allegra A. G., Di Salvo E., Gangemi S., Innao V., Musolino C., Pugliese M., Ventura-Spagnolo E.   +7 more
core   +1 more source